Core Viewpoint - As of May 29, 2023, AAPG's stock price increased by 2.43%, reaching $25.02 per share, with a total market capitalization of $2.18 billion. The company reported a total revenue of 981 million RMB for the year ending December 31, 2024, representing a year-on-year growth of 341.77%, while the net profit attributable to shareholders was -405 million RMB, showing a growth of 56.2% year-on-year [1][2]. Company Overview - AAPG is a biopharmaceutical company based in China, focusing on global markets, dedicated to developing innovative drugs for the treatment of cancer, hepatitis B, and age-related diseases [2]. - The company was listed on the Hong Kong Stock Exchange on October 28, 2019, under the stock code 6855.HK [2]. - AAPG has developed a proprietary drug design platform targeting protein-protein interactions, positioning itself at the forefront of new drug development in the apoptosis pathway [2]. Product Pipeline and Clinical Development - The company has established a pipeline of nine Class 1 small molecule new drugs that have entered clinical development, including inhibitors targeting key proteins in the apoptosis pathway such as Bcl-2, IAP, and MDM2-p53 [2]. - AAPG is the only innovative company globally with clinical development products in all key proteins of the apoptosis pathway [2]. - Currently, the company is conducting over 40 clinical trials across China, the United States, Australia, and Europe [2]. Key Product and Regulatory Approvals - The core product, Orebatinib (brand name: Nairike), used for treating chronic myeloid leukemia, has received priority review and breakthrough therapy designation from the China National Medical Products Administration (NMPA) and has been approved for sale in China [2]. - Nairike has also been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2022) [2]. - The product has received fast track designation, orphan drug designation from the FDA, and orphan drug designation from the EU [2]. Research and Development Capabilities - AAPG has undertaken multiple national science and technology major projects, including five related to "Major New Drug Creation" and one related to "Major Infectious Disease Prevention and Control" [2]. - The company has established a global intellectual property layout and formed partnerships with leading biotech and pharmaceutical companies and academic institutions, including UNITY, MD Anderson, Mayo Clinic, Dana-Farber Cancer Institute, Merck, AstraZeneca, and Pfizer [2]. - AAPG is building a high-standard commercialization and marketing team while continuously enhancing its R&D capabilities to accelerate the clinical development of its product pipeline [2].
亚盛医药上涨2.43%，报25.02美元/股，总市值21.80亿美元